New York, June 4, 2026, 19:00 EDT
LeMaitre Vascular shares gained 2.0% to $93.56 late Thursday in U.S. trading. The move came with the medical-technology group trading firmer and as traders eyed a planned quarterly dividend from the vascular-device maker. The stock traded in a $92.15 to $95.57 range. Market cap stood around $2.15 billion.
LeMaitre’s move comes as the company looks to hold investor backing after posting a solid first-quarter report in May. Bigger medical device stocks have seen new buying, too. The iShares U.S. Medical Devices ETF gained 2.8%. That compares to a 0.4% uptick for the SPDR S&P 500 ETF.
LeMaitre’s quarterly filing said the board has cleared a $0.25 per share dividend. The payout date is June 4 for investors who own shares as of May 21. The company said future dividends still need sign-off from the board each quarter.
Burlington, Massachusetts-based LeMaitre saw Q1 sales climb 11% to $66.6 million from the same period last year, with diluted EPS up 42% to 68 cents. Organic sales, which exclude currency swings and some transactions, increased 10%.
LeMaitre Vascular CEO George LeMaitre pointed to “higher ASPs,” or average selling prices, plus growth into new regions and tighter spending as drivers for the latest quarter. The company now sees 2026 sales between $277 million and $283 million, and EPS in a range of $2.93 to $3.08. GlobeNewswire
LeMaitre trades with a tight focus, according to its filing. The company sells medical devices and offers human tissue cryopreservation services, mainly for peripheral vascular disease outside the heart and brain and for end-stage renal and cardiovascular disease. Biologic products were 53% of its global sales last quarter.
LeMaitre is on the health-care investor circuit in June, with management lined up for a Jefferies Global Healthcare Conference fireside chat in New York June 3. The team is also presenting at the Goldman Sachs Annual Global Healthcare Conference in Miami Beach June 10.
Medtronic jumped 5.1% after Reuters said the company topped quarterly revenue and adjusted earnings forecasts thanks to stronger demand for heart devices. Other names in medical devices moved higher too, with Merit Medical up 4.0% and Artivion gaining 1.3%. The sector set a positive tone.
LeMaitre’s competitive picture isn’t clear-cut. The company pitches a focus on niche products with few competitors and a direct sales approach. But in its filing, LeMaitre admits it has struggled in crowded markets like polyester vascular grafts, where bigger firms have lower production costs and more resources.
The outlook isn’t all clear. If price gains cool, regulatory sign-offs get delayed, direct-sales doesn’t deliver, or forex hits harder, the 2026 targets could look shaky. On the May earnings call, when asked about how much risk was left in the guidance, George LeMaitre said, “There’s always risk.” Investing
Investors have just a few things on their radar right now: if the medical-device rally keeps going, if LeMaitre brings anything new at Goldman next week, and whether second-quarter sales fall inside the $70.5 million to $72.5 million range the company gave. For now, Thursday’s move looks like a sector-and-dividend play rather than any new story for the company.
